BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37857049)

  • 1. Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
    Grottker F; Gehre S; Reichardt CM; Sengedorj A; Jost T; Rieckmann T; Hecht M; Gostian AO; Frey B; Fietkau R; Gaipl US; Rückert M
    Neoplasia; 2023 Nov; 45():100944. PubMed ID: 37857049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells.
    Wimmer S; Deloch L; Hader M; Derer A; Grottker F; Weissmann T; Hecht M; Gostian AO; Fietkau R; Frey B; Gaipl US
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
    Valentini C; Ebert N; Koi L; Pfeifer M; Löck S; Erdmann C; Krause M; Baumann M
    Radiother Oncol; 2023 Jun; 183():109546. PubMed ID: 36813172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of differences in radiation-induced immunogenicity parameters between HPV-positive and HPV-negative human HNSCC cell lines.
    Schneider K; Bol V; Grégoire V
    Radiother Oncol; 2017 Sep; 124(3):411-417. PubMed ID: 28916224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
    Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
    Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune microenvironment of human papillomavirus-positive head and neck squamous cell carcinoma.
    Zhu D; He X; Li Y; Li G; Chen M
    Sci Prog; 2024; 107(1):368504241237888. PubMed ID: 38545800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
    Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
    APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
    Salazar CR; Smith RV; Garg MK; Haigentz M; Schiff BA; Kawachi N; Anayannis N; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
    Head Neck Pathol; 2014 Mar; 8(1):77-87. PubMed ID: 24002971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell Carcinoma.
    Mytilineos D; Ezić J; von Witzleben A; Mytilineos J; Lotfi R; Fürst D; Tsamadou C; Theodoraki MN; Oster A; Völkel G; Kestler HA; Brunner C; Schuler PJ; Doescher J; Hoffmann TK; Laban S
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Li C; Johnson DE
    Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.